PharmaLectures.com

Courses › Country and business playbooks › Selling into Europe as a biologics and biosimilars maker from Japan

Selling into Europe as a biologics and biosimilars maker from Japan

Launch your Japanese biologic in Europe without losing months to rework and rejections.

  • 12 audio modulesthree lengths each
  • 2 h to 10 hbriefing to expanded
  • Workbook, transcript, certificateand a recorded quiz per module
  • Japan, Biologics and biosimilarswho it is written for

Why this training matters

Your dossier reaches the Day 120 list of questions with comparability gaps nobody caught. Then the German assessment body asks for a comparator your Japanese trials never used. Each round restarts a clock, and a competitor's biosimilar takes the formulary slot you planned for.

What changes after this course

Your team files with the European Medicines Agency, the German and French assessment bodies and EudraVigilance using the right documents the first time. You hold a certificate for each learner and a training record per person, ready to show an auditor.

Watch the pitch

3:43 on how an audio course is bought, listened to and recorded. Full screen, one click.

Watch the pitch3:43, full screen, one click

What this course gives your people

Your regulatory lead drafts the centralized procedure application knowing what the Committee for Medicinal Products for Human Use will ask about comparability, and answers it in the dossier instead of during a clock stop. The health technology assessment file names the right comparator the first time. Legal applies Directive 2001/83/EC, including the abbreviated route for biosimilars, without rounds of back and forth.

Pricing managers stop guessing. They walk into Germany's early benefit assessment and the French Transparency Committee with evidence shaped for each, and they know which country must not launch first because of international reference pricing. Negotiators bring a dossier to the national association of sickness funds, and access teams know which experts and patient groups to approach, and when.

Patent attorneys file Supplementary Protection Certificates and map the 12-month Paris Convention priority period before a date slips. Logistics leads document the cold chain to Good Distribution Practice and fit the safety features Directive 2011/62/EU requires. Safety officers send adverse event reports to EudraVigilance in the right format and on time, so the market authorization stays clean.

Product managers read national substitution rules before they write the sales plan for a biosimilar, and they stop pushing one story across the German, French and British systems. Clinical directors check their real-world evidence plans against the European Health Data Space rules and change the development plan while a change is still easy.

Who needs this training

  • Regulatory Affairs Manager

    The Day 120 list of questions arrives full of comparability queries on your Japanese quality data. You have already answered most of them in the dossier, because you wrote it for the committee that reads it.

  • Market Access Specialist

    You sit across from the German Federal Joint Committee with a comparator your Japanese trials never used. This course gives you the evidence and the price logic to hold your position.

  • Supply Chain Lead

    A Good Distribution Practice inspector asks for the temperature record behind one shipment. You hand over a file that answers the question, not a folder you hope covers it.

  • Pharmacovigilance Officer

    A serious case report is due in EudraVigilance and the format is rejected. You know the fields and the deadline before that day arrives.

  • Product Manager, Biosimilars

    Your launch plan assumes pharmacists can substitute your product. In one country they cannot. You find that out before launch planning, not after.

Roles: Owner, CEO and board, Business development and export sales, Regulatory affairs, Quality assurance and Qualified Person

Businesses: Biologics and biosimilars

Countries: Japan

Selling into: Europe and the UK

Courses are in English. Other languages on request.

After this course your people can

  1. Draft a centralized procedure application that answers the Day 120 comparability questions before the committee asks them.
  2. Choose a comparator for a health technology assessment submission and defend it when a national body objects.
  3. Prepare for joint clinical assessment under Regulation (EU) 2021/2282 where your product falls in scope.
  4. Set the launch order of European countries as a pricing decision, with international reference pricing in view.
  5. File a Supplementary Protection Certificate application for your biologic and track the filing deadline.
  6. Document a cold chain so it holds up in a Good Distribution Practice inspection.
  7. Submit adverse event reports to EudraVigilance in the correct format before the deadline.

What the company gets

  • Your dossiers reach the European Medicines Agency with the comparability questions already answered, so fewer clock stops eat into your launch date.
  • Your pricing team can say why Germany or France comes first and what that choice does to prices in other countries.
  • Inspectors get a cold chain file that answers their questions in the order they ask them.
  • Each learner finishes a recorded multiple-choice questionnaire per module and receives a certificate, so an auditor sees who was trained, on what, and when.

The evidence: questionnaire, training record, certificate

EU GMP Chapter 2, section 2.11, and 21 CFR 211.25 both ask for training that is documented and shown to work. This is what each learner leaves behind.

A recorded questionnaire per module

Every one of the 12 modules ends with a multiple-choice questionnaire. The result is recorded per person with a timestamp, whichever of the three lengths the person listened to.

A per-person training record

The export lists each learner, each module, the result and the date, which is the training record EU GMP Chapter 2 and 21 CFR 211.25 ask you to keep and the first thing an inspector asks for.

A certificate per learner

Name, company, course, hours, the guideline version taught and the date. It documents in-company training; it is not a professional qualification or an accreditation.

Your pass mark, your rule

There is no fixed pass mark. Your quality or human-resources manager decides what counts as passed and when a module is retaken, exactly as your training procedure says.

Delivered within 72 hours of payment, with the workbook, the full transcript and a source for every fact in the audio.

How long it takes, by who is listening

Nobody spends a day in a classroom. Every module exists in three lengths; a person takes the length their role needs, and every length ends with the same recorded questionnaire, so the training record is complete either way.

Briefing2 h10 min a module, for executives, sales and anyone who must know the rules, not run them
Standard5 h25 min a module, for regulatory, quality and business-development staff
Expanded10 h50 min a module, for technical staff who run the procedure day to day
Who takes this courseLengthTotal time
Owner, CEO and boardBriefing2 h
Business development and export salesBriefing2 h
Regulatory affairsStandard5 h
Quality assurance and Qualified PersonStandard5 h

Course outline: 12 modules

12 modules. Under each title are the three things the listener can do afterwards; the audio itself runs 10 to 50 minutes depending on the length chosen.

  1. 1Take your biologic through the centralized procedure without clock stops

    • Why Japanese quality data draws comparability questions at Day 120, and how to answer them upfront.
    • How to book scientific advice from the Committee for Medicinal Products for Human Use before you file.
    • The pre-submission checks that stop your dossier bouncing at validation.
  2. 2Format health technology assessment submissions that European bodies accept

    • How to pick a comparator European assessment bodies accept when your Japanese trials used another.
    • What to do when a national body wants an endpoint your Japanese trials never measured.
    • When European Union joint clinical assessment under Regulation (EU) 2021/2282 saves work, and when not.
  3. 3Set biologic prices for Germany, France and other markets that hold up

    • How to show additional benefit in Germany's early benefit assessment so your price holds.
    • The benefit and improvement ratings the French Transparency Committee gives, and what drives them.
    • Why launching in the wrong country first pulls prices down elsewhere through reference pricing.
  4. 4Negotiate reimbursement terms with national sickness funds and win listing

    • How to build the dossier your negotiators take to Germany's national association of sickness funds.
    • The data points payers look for before they list your biologic on a formulary.
    • What to do when talks stall and the German arbitration board is the next step.
  5. 5Win the support of assessment bodies and patient groups before they decide

    • How to spot the clinical experts whose opinions shape a national assessment, before the meeting.
    • When to bring patient groups into your access plan, and when it is already too late.
    • Why a submission that ignores local patient needs meets a cold reception, and how to fix yours.
  6. 6Apply Directive 2001/83/EC to choose the right route for each biologic

    • How Directive 2001/83/EC decides which legal route your biologic application must take.
    • The comparability data that lets your biosimilar rely on the reference product under Article 10(4).
    • How the data protection period on a reference biologic sets your earliest filing and launch date.
  7. 7Secure patents and Supplementary Protection Certificates across Europe

    • How to file a Supplementary Protection Certificate before the filing window closes.
    • How the 12-month Paris Convention priority period shapes where and when you file in Europe.
    • What to do when a competitor's overlapping patent threatens your launch.
  8. 8Build a European supply chain that passes Good Distribution Practice checks

    • How to document your cold chain so a Good Distribution Practice inspector has nothing to write up.
    • The unique identifier and tamper-evidence that Directive 2011/62/EU requires on your packs.
    • Why temperature data that satisfied you in Japan can fail a European inspection.
  9. 9Position your biosimilar against originator biologics in each European market

    • How to use the abbreviated biosimilar pathway to reach the market sooner.
    • How interchangeability and pharmacy substitution rules differ from one European country to the next.
    • What to stress in your dossier when many biosimilars already compete for the same prescribers.
  10. 10Report to EudraVigilance on time and keep fines away

    • How to format adverse event reports so EudraVigilance accepts them the first time.
    • The deadlines for serious and non-serious case reports, and how to track them to avoid penalties.
    • What to do when a safety signal appears and withdrawal of your product is on the table.
  11. 11Adapt your market access plan to each European healthcare system

    • Why one market access plan fails across Europe, and how to split it by healthcare system.
    • How Germany, France and the United Kingdom each fund a biologic and judge its value.
    • Where to adapt your evidence and message before the first payer meeting in each region.
  12. 12Prepare real-world evidence plans that meet European Health Data Space rules

    • How the European Health Data Space changes access to the data behind your real-world evidence.
    • When the new rules reach your data sources, so your plan does not rest on one that closes.
    • What to change in your clinical development plan now to meet the coming European rules.
The founders

One of us was inspected. The other one pays for the training.

Every claim below is sourced on the about page: the medicines register, the Lithuanian Pharmaceutical Union board list, the university directory.

Justina Krukonytė-Racz

Justina Krukonytė-Racz

Co-founder. Licensed pharmacist.

GDPResponsible PersonWarehouse & logistics

Licensed pharmacist. Responsible Person at Tamro (PHOENIX group), where she led the GDP set-up of the distribution centre.

The Responsible Person is the named person the regulator holds accountable for every pallet that leaves the building.

She writes the modules around the procedures a GDP inspection checks. Board member of Lithuanian Pharmaceutical Union.

Listed in the Lithuanian medicines register as Pharmacist.

Prof. Ben Racz

Prof. Ben Racz

Co-founder. Builds the platform and is responsible for delivery, records and pricing.

Platform & deliveryQuantitative researchCarnegie Mellon

He was Professor of the Practice at the College of Engineering at Carnegie Mellon University, where he taught Advanced Quantitative Finance and Algorithmic Trading to MSc students.

He is the founder and Managing Director of Algorithmic Sciences, a scientific research and consulting firm. Earlier he co-founded a data-driven growth consultancy, a data-science based wholesale trading company and an information security firm.

More about Ben at benracz.com

Questions about this course

Is there a certificate?

Yes. Every learner who finishes the course receives a certificate in their own name, and every module ends with a recorded multiple-choice questionnaire, so the certificate sits on top of a per-person training record. The certificate documents in-company training; it is not a professional qualification or an accreditation, and your quality or human-resources manager sets the pass mark and decides when a module is retaken.

How long does the course take?

12 modules, each in three lengths: a 10-minute briefing, a 25-minute standard run and a 50-minute expanded walk-through. The whole course takes 2 h in the briefing length and 10 h in the expanded length. People take the length their role needs, and every length ends with the same recorded questionnaire, so the training record is complete either way.

Who should take this course?

It is written for Japan, Biologics and biosimilars. Owners, managers and sales staff hear the briefing length, regulatory, quality and business-development staff take the standard run, and the people who run the procedure every day get the expanded version. One licence covers one named person on this course for a year, so the same title can be rolled out across a whole team at once.

Is this training accepted as a GMP training record by an auditor?

EU GMP Chapter 2 and 21 CFR 211.25 require documented, effective training, and that is what the course produces: a recorded multiple-choice result per module and per person, a certificate per learner and a transcript of what was taught. No provider can promise acceptance by a specific inspector; the record is built to answer what inspectors ask for, and your quality manager decides the pass mark.

How is it delivered and how fast?

The course arrives as audio files with a companion workbook, a full transcript and the questionnaire per module, within 72 hours of your payment arriving. You host the files on your own system or share them as you like; there is no platform to log into and no learner management system to set up. The free sample module arrives on request, before any purchase.

What does it cost per learner?

The list price is 9 euros per module, per learner, per year, so this course is 108 euros for one person for twelve months. The price per learner falls as more people take the same course: 10 learners pay 10 percent less and the discount keeps growing to 50 percent at 1000 learners. Type a number on the price panel and the yearly total appears.

Get this course for your team

One licence is one person on this course for a year. All three lengths, the workbook, the certificate and the training record are included in every purchase. Pick how many people, add it to the cart, and you have an invoice in your inbox.

Free sample module

Hear one full module before you spend a cent. Send your company and the role you want trained, and a complete sample module comes back with its workbook and transcript.

Connect on WhatsApp

or email [email protected], or ask for a written quote for your team